DE60042014D1 - Methode zur radiomarkierung von proteinen mit yttrium-90 - Google Patents

Methode zur radiomarkierung von proteinen mit yttrium-90

Info

Publication number
DE60042014D1
DE60042014D1 DE60042014T DE60042014T DE60042014D1 DE 60042014 D1 DE60042014 D1 DE 60042014D1 DE 60042014 T DE60042014 T DE 60042014T DE 60042014 T DE60042014 T DE 60042014T DE 60042014 D1 DE60042014 D1 DE 60042014D1
Authority
DE
Germany
Prior art keywords
yttrium
proteins
radiomarking
kits
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042014T
Other languages
English (en)
Inventor
Paul Chinn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DE60042014D1 publication Critical patent/DE60042014D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE60042014T 1999-03-01 2000-02-29 Methode zur radiomarkierung von proteinen mit yttrium-90 Expired - Lifetime DE60042014D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25933899A 1999-03-01 1999-03-01
PCT/US2000/005078 WO2000052031A2 (en) 1999-03-01 2000-02-29 Kit for radiolabeling proteins with yttrium-90

Publications (1)

Publication Number Publication Date
DE60042014D1 true DE60042014D1 (de) 2009-05-28

Family

ID=22984528

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60042014T Expired - Lifetime DE60042014D1 (de) 1999-03-01 2000-02-29 Methode zur radiomarkierung von proteinen mit yttrium-90
DE1156835T Pending DE1156835T1 (de) 1999-03-01 2000-02-29 Kit zur radiomarkierung von proteinen mit yttrium-90

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1156835T Pending DE1156835T1 (de) 1999-03-01 2000-02-29 Kit zur radiomarkierung von proteinen mit yttrium-90

Country Status (36)

Country Link
US (3) US6994840B1 (de)
EP (2) EP1156835B1 (de)
JP (1) JP4558947B2 (de)
KR (1) KR100734023B1 (de)
CN (1) CN1251767C (de)
AT (1) ATE428446T1 (de)
AU (1) AU780311B2 (de)
BG (1) BG65568B1 (de)
BR (1) BR0008635A (de)
CA (1) CA2362908C (de)
CY (1) CY1109211T1 (de)
CZ (1) CZ20013127A3 (de)
DE (2) DE60042014D1 (de)
DK (1) DK1156835T3 (de)
EE (1) EE05582B1 (de)
ES (1) ES2165830T3 (de)
GR (1) GR20010300078T1 (de)
HK (1) HK1045656B (de)
HR (1) HRP20010713A2 (de)
HU (1) HU227986B1 (de)
IL (2) IL145112A0 (de)
ME (1) ME00783B (de)
MX (1) MXPA01008745A (de)
MY (1) MY133346A (de)
NO (1) NO330728B1 (de)
NZ (1) NZ513667A (de)
PL (1) PL204239B1 (de)
PT (1) PT1156835E (de)
RS (1) RS50342B (de)
RU (1) RU2221807C2 (de)
SI (1) SI1156835T1 (de)
SK (1) SK287650B6 (de)
TW (1) TWI283178B (de)
UA (1) UA75036C2 (de)
WO (1) WO2000052031A2 (de)
ZA (1) ZA200106945B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
ATE327004T1 (de) 2000-10-02 2006-06-15 Chiron Corp Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40
US6696060B2 (en) * 2001-06-14 2004-02-24 Clearant, Inc. Methods for sterilizing preparations of monoclonal immunoglobulins
US7252799B2 (en) 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
US6783968B2 (en) 2001-09-24 2004-08-31 Clearant, Inc. Methods for sterilizing preparations of glycosidases
US6974563B2 (en) 2002-06-18 2005-12-13 Lynntech, Inc. Ion exchange materials for the separation of 90Y from 90SR
BRPI0407031A (pt) * 2003-01-27 2006-01-17 Biogen Idec Inc Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
NZ606996A (en) * 2003-04-15 2014-08-29 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease
WO2005044855A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
ATE476448T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat- abstossung
CA2544852A1 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
PT1682177E (pt) 2003-11-04 2010-11-29 Xoma Technology Lt Utilização de anticorpos antagonistas anti-cd40 para o tratamento da leucemia linfocítica crónica
DK1684869T3 (da) 2003-11-04 2011-10-31 Novartis Vaccines & Diagnostic Fremgangsmåde til terapi af B-celle-relaterede cancersygdomme
ES2429564T3 (es) 2005-05-18 2013-11-15 Novartis Ag Procedimientos para el diagnóstico y tratamiento de enfermedades que tienen un componente autoinmune y/o inflamatorio
EA018301B1 (ru) 2006-04-21 2013-07-30 Новартис Аг Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
EA201170204A1 (ru) 2008-07-16 2011-08-30 ХЬЮМЭБС ЭлЭлСи Антитела, нейтрализующие цитомегаловирус человека, и их применение
EP3009449B1 (de) 2008-07-16 2018-06-06 Institute for Research in Biomedicine Das humane cytomegalovirus neutralisierende antikörper und deren anwendung
KR101732056B1 (ko) 2008-07-25 2017-05-02 인스티튜트 포 리서치 인 바이오메드슨 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
CA2739551C (en) 2008-10-13 2019-03-05 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
WO2011092593A2 (en) 2010-01-20 2011-08-04 Institute For Research In Biomedicine Hiv-1 neutralizing antibodies and uses thereof
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
WO2011147762A2 (en) * 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
KR20130132935A (ko) * 2010-12-22 2013-12-05 지이 헬쓰케어 리미티드 Ｎｏｔａ에 의해 복합체를 형성한 알루미늄―〔１８〕플루오라이드로 표지된 ｈｅｒ２ 결합 펩티드
EP2734545B1 (de) 2011-07-18 2019-03-27 Institute for Research in Biomedicine Neutralisierende antiinflueanza-a-virus-antikörper und ihre verwendung
EP2828293B1 (de) 2012-03-20 2017-10-25 Humabs Biomed S.A. Antikörper zur neutralisierung von rsv, mpv und pvm sowie verwendungen davon
RU2537175C2 (ru) * 2013-03-26 2014-12-27 Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации Способ получения радиоиммунного препарата для диагностики и терапии онкологических заболеваний
MX2016001851A (es) 2013-08-13 2016-05-16 Sanofi Sa Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
LT3052192T (lt) 2013-10-02 2020-12-10 Medimmune, Llc Neutralizuojantys antikūnai prieš gripą a ir jų naudojimas
CA2954780A1 (en) 2014-07-15 2016-01-21 Medimmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
WO2016055950A1 (en) 2014-10-08 2016-04-14 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
BR122020023406B1 (pt) 2014-11-18 2023-10-31 Institut Pasteur Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, moléculas de ácido nucleico, vetor, célula isolada, composição farmacêutica, usos dos mesmos, e kit de partes
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
HRP20211510T1 (hr) 2015-06-01 2021-12-24 Medimmune, Llc Neutralizirajuće vezujuće molekule protiv influence i njihova uporaba
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
EP3402513A4 (de) 2016-01-13 2019-10-23 Medlmmune, LLC Verfahren zur behandlung von influenza a
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
BR112019021824A2 (pt) 2017-04-19 2020-06-02 Institute For Research In Biomedicine Vacinas contra a malária e anticorpos de ligação a esporozoítos de plasmódio
EP3635012A4 (de) * 2017-05-12 2020-12-30 Memorial Sloan-Kettering Cancer Center Verwendung von anti-b7h3-antikörpern zur behandlung von krebs im zentralen nervensystem
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
MX2021006756A (es) 2018-12-19 2021-09-28 Humabs Biomed Sa Anticuerpos que neutralizan el virus de la hepatitis b y usos de los mismos.
CN114630680A (zh) 2019-08-29 2022-06-14 维尔生物科技有限公司 用于治疗乙型肝炎病毒感染的抗体组合物和方法
CN111116701A (zh) * 2019-11-14 2020-05-08 浙江普罗亭健康科技有限公司 一种用于蛋白金属标记的中间体及其制备方法、用途
BR112022026316A2 (pt) 2020-06-24 2023-03-07 Vir Biotechnology Inc Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
TW202245838A (zh) 2021-01-26 2022-12-01 美商維爾生物科技股份有限公司 用於治療b型肝炎病毒感染的組成物及方法
WO2024068944A1 (en) 2022-09-30 2024-04-04 Sanofi Anti-cd28 antibodies

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994966A (en) 1972-09-28 1976-11-30 The Board Of Trustees Of The Leland Stanford Junior University Chelating agents
US4043998A (en) 1974-10-09 1977-08-23 The Board Of Trustees Of The Leland Stanford Junior University 1-(P-benzenediazonium)-ethylenediamine tetraacetic acid
US4315851A (en) 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460559A (en) 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460561A (en) 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4622420A (en) 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4707352A (en) 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4636380A (en) 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4722892A (en) 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4824986A (en) 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4926869A (en) 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
AU593611B2 (en) 1986-02-14 1990-02-15 Nihon Medi-Physics Co., Ltd. High molecular compounds having amino groups, and their utilization
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
EP0484989B1 (de) * 1986-09-05 1996-04-24 GANSOW, Otto A. Polysubstituierte Diethylentriamin Chelate zur Bildung einer Metall-Chelat-Protein Konjugierung
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5034223A (en) 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5217704A (en) 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
AU619218B2 (en) 1987-11-06 1992-01-23 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
WO1989011475A1 (en) 1988-05-25 1989-11-30 The United States Of America, As Represented By Th Macrocyclic chelates and methods of use thereof
US4923985A (en) 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US5059518A (en) 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5376356A (en) 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
US5162115A (en) 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5219556A (en) 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5009069A (en) 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
WO1992007466A1 (en) 1990-11-05 1992-05-14 Bristol-Myers Squibb Company Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
US5208008A (en) 1990-11-14 1993-05-04 University Of Pittsburgh Regioselective chemical modification of monoclonal antibodies
JPH05505680A (ja) 1991-01-11 1993-08-19 コーブ　ラボラトリーズ　インコーポレイテッド 乾燥または凍結乾燥した細胞または細胞―様物質を使用する循環抗体の型を検定する方法
US5403573A (en) 1992-04-23 1995-04-04 The Curators Of The University Of Missouri Radiolabeled protein composition and method for radiation synovectomy
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
DE122004000036I1 (de) 1992-11-13 2005-07-07 Biogen Idec Inc Therapeutische Verwendung von chimerischen und markierten Antik¦rper gegen menschlichen B Lymphozyt beschr{nkter Differenzierung antigen f}r die Behandlung von B-Zell-Lymphoma.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5766751A (en) 1994-01-24 1998-06-16 Sumitomo Chemical Company, Ltd. Laminate, laminate film and shaped article comprising inorganic laminar compound
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5728369A (en) 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5942210A (en) * 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US6300143B1 (en) 1999-03-01 2001-10-09 Idec Pharmaceuticals Corporation Electrochemiluminescent assays for eukaryotic cells
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90

Also Published As

Publication number Publication date
KR20020002474A (ko) 2002-01-09
ATE428446T1 (de) 2009-05-15
NO330728B1 (no) 2011-06-27
PT1156835E (pt) 2009-07-24
US7618613B2 (en) 2009-11-17
GR20010300078T1 (en) 2002-01-31
CA2362908C (en) 2012-01-31
EE05582B1 (et) 2012-10-15
RU2221807C2 (ru) 2004-01-20
DK1156835T3 (da) 2009-08-03
YU61701A (sh) 2004-05-12
HK1045656B (zh) 2006-09-22
IL145112A0 (en) 2002-06-30
HK1045656A1 (en) 2002-12-06
NZ513667A (en) 2001-09-28
TWI283178B (en) 2007-07-01
BG65568B1 (bg) 2008-12-30
HUP0105489A2 (hu) 2002-05-29
HUP0105489A3 (en) 2005-10-28
HU227986B1 (en) 2012-07-30
JP2002538164A (ja) 2002-11-12
CN1251767C (zh) 2006-04-19
CA2362908A1 (en) 2000-09-08
NO20014239D0 (no) 2001-08-31
MXPA01008745A (es) 2002-04-24
US20060067884A1 (en) 2006-03-30
US6994840B1 (en) 2006-02-07
EP2011520A1 (de) 2009-01-07
ME00783B (me) 2012-03-20
DE1156835T1 (de) 2002-05-23
EP1156835B1 (de) 2009-04-15
CY1109211T1 (el) 2014-07-02
ES2165830T3 (es) 2009-06-19
IL145112A (en) 2007-05-15
RS50342B (sr) 2009-11-10
US20070297978A1 (en) 2007-12-27
SK12172001A3 (sk) 2002-05-09
SI1156835T1 (sl) 2009-08-31
HRP20010713A2 (en) 2002-12-31
NO20014239L (no) 2001-11-01
UA75036C2 (uk) 2006-03-15
WO2000052031A2 (en) 2000-09-08
BG105853A (en) 2002-06-28
CZ20013127A3 (cs) 2002-02-13
AU780311B2 (en) 2005-03-17
US7229620B2 (en) 2007-06-12
PL204239B1 (pl) 2009-12-31
SK287650B6 (sk) 2011-05-06
AU4004600A (en) 2000-09-21
JP4558947B2 (ja) 2010-10-06
MY133346A (en) 2007-11-30
EP1156835A2 (de) 2001-11-28
CN1345249A (zh) 2002-04-17
ES2165830T1 (es) 2002-04-01
PL350551A1 (en) 2002-12-16
KR100734023B1 (ko) 2007-06-29
ZA200106945B (en) 2002-11-22
WO2000052031A3 (en) 2001-03-01
BR0008635A (pt) 2001-12-26
EE200100461A (et) 2002-10-15

Similar Documents

Publication Publication Date Title
DE60042014D1 (de) Methode zur radiomarkierung von proteinen mit yttrium-90
HK1063188A1 (en) Peptide for the diagnosis and therapy of alzeimer's disease
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
DK0927192T3 (da) Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling
ATE444967T1 (de) Spezifische bindungsmittel von human angiopoietin-2
AU8506601A (en) Binding polypeptides for b lymphocyte stimulator protein (blys)
DE69321555T2 (de) ECK-Rezeptor-Liganden
DE3781005D1 (de) Adsorptionsmittel fuer chromatographie, methode zur herstellung desselben und saeulensystem fuer chromatographie.
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DE69133068T2 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
ATE417056T1 (de) Verfahren zur proteinreinigung
ATE119543T1 (de) Produktion von proteinen in aktiver form.
IS4957A (is) Hreinsuð prótein, samskeyttar DNA raðir og aðferðir til að stýra þroskun kaffiplantna
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
de la Torre et al. Hydroxyapatite-based 99Mo/99mTc and 188W/188Re generator systems
DK381787D0 (da) Rensede antigener med vaccineegenskaber mod b. pertussis, midler, navnlig rekombinant-dna, til fremstilling deraf og vaccinepraeparater indeholdende disse
ES284027U (es) Cama clinica perfeccionada

Legal Events

Date Code Title Description
8364 No opposition during term of opposition